News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
C4 Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Business
The Next Generation: Top 20 Life Science Startups to Watch in 2017
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
January 3, 2017
·
11 min read
·
Mark Terry
Business
What You Need to Know About C4 Therapeutics
January 3, 2017
·
6 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026
·
8 min read
Press Releases
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 9, 2026
March 9, 2026
·
1 min read
Press Releases
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
·
12 min read
Press Releases
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
February 23, 2026
·
7 min read
Press Releases
C4 Therapeutics to Participate in Upcoming March 2026 Conferences
February 23, 2026
·
1 min read
Press Releases
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 9, 2026
February 10, 2026
·
1 min read
Press Releases
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
·
1 min read
Press Releases
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 26, 2026
January 27, 2026
·
1 min read
Press Releases
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 15, 2026
·
10 min read
Press Releases
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 26, 2025
·
1 min read
